Document_And_Entity_Informatio
Document And Entity Information (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Apr. 15, 2014 | |
Document and Entity Information [Abstract] | ' | ' |
Entity Registrant Name | 'AMARILLO BIOSCIENCES INC | ' |
Document Type | '10-K | ' |
Current Fiscal Year End Date | '--12-31 | ' |
Entity Common Stock, Shares Outstanding | ' | 73,291,008 |
Entity Public Float | $52,710 | ' |
Amendment Flag | 'false | ' |
Entity Central Index Key | '0001014763 | ' |
Entity Current Reporting Status | 'Yes | ' |
Entity Voluntary Filers | 'No | ' |
Entity Filer Category | 'Smaller Reporting Company | ' |
Entity Well-known Seasoned Issuer | 'No | ' |
Document Period End Date | 31-Dec-13 | ' |
Document Fiscal Year Focus | '2013 | ' |
Document Fiscal Period Focus | 'FY | ' |
Balance_Sheets
Balance Sheets (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Current assets: | ' | ' |
Cash and cash equivalents | $6,539 | $7,261 |
Prepaid expense and other current assets | 61,953 | 13,674 |
Total current assets | 68,492 | 20,935 |
Patents, net | 93,039 | 94,100 |
Total assets | 161,531 | 115,035 |
Current liabilities: | ' | ' |
Accounts payable and accrued expenses | 288,244 | 360,353 |
Accrued interest – related parties | 1,050,671 | 951,442 |
Accrued expenses – related party | 78,360 | 78,360 |
Derivative liabilities | ' | 4,217 |
Notes payable – related parties | 3,527,043 | 2,847,958 |
Total current liabilities | 4,944,318 | 4,242,330 |
Total liabilities | 4,944,318 | 4,242,330 |
Stockholders' deficit | ' | ' |
Preferred stock, $0.01 par value: Authorized shares – 10,000,000 Issued and outstanding shares – 3,262 at December 31, 2013 and at December 31, 2012 | 33 | 33 |
Common stock, $0.01par value: Authorized shares - 100,000,000 Issued and outstanding shares – 73,291,008 at December 31, 2013 and 73,554,897 at December 31, 2012 | 732,910 | 735,549 |
Additional paid-in capital | 31,968,516 | 31,966,377 |
Accumulated deficit | -37,484,246 | -36,829,254 |
Total stockholders' deficit | -4,782,787 | -4,127,295 |
Total liabilities and stockholders’ deficit | $161,531 | $115,035 |
Balance_Sheets_Parentheticals
Balance Sheets (Parentheticals) (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Preferred stock, par value (in Dollars per share) | $0.01 | $0.01 |
Preferred stock, Authorized shares | 10,000,000 | 10,000,000 |
Preferred stock, Issued shares | 3,262 | 3,262 |
Preferred stock, Outstanding shares | 3,262 | 3,262 |
Common stock, par value (in Dollars per share) | $0.01 | $0.01 |
Common stock, Authorized shares | 100,000,000 | 100,000,000 |
Common stock, Issued shares | 73,291,008 | 73,554,897 |
Common stock, Outstanding shares | 73,291,008 | 73,554,897 |
Statements_of_Operations
Statements of Operations (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Revenues: | ' | ' |
Product sales | ' | $530 |
Total revenues | ' | 530 |
Cost of revenues: | ' | ' |
Product sales | ' | 212 |
Total cost of revenues | ' | 212 |
Gross margin | ' | 318 |
Operating expenses: | ' | ' |
Research and development expenses | 132,962 | 199,599 |
Selling, general and administrative expenses | 433,193 | 355,327 |
Total operating expenses | 566,155 | 554,926 |
Operating loss | -566,155 | -554,608 |
Other income (expense): | ' | ' |
Gain on debt conversion | ' | 15,220 |
Change in fair value of derivatives | 4,217 | 44,096 |
Interest expense | -103,366 | -155,555 |
Debt Forgiveness Income | 42,702 | ' |
Net loss | -622,602 | -650,847 |
Preferred stock dividend | -32,390 | -30,851 |
Net loss applicable to common shareholders | ($654,992) | ($681,698) |
Basic and diluted net loss per average share available to common shareholders (in Dollars per share) | ($0.01) | ($0.01) |
Weighted average common shares outstanding – basic and diluted (in Shares) | 73,443,558 | 73,367,810 |
Statements_of_Stockholders_Def
Statements of Stockholders’ Deficit (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Balance | ($4,127,295) | ($4,103,462) | ' |
Net income | -622,602 | -650,847 | ' |
Stock repurchase-debt settlement agreement | -500 | ' | ' |
Issuance of preferred stock for debt/dividends | ' | 133,878 | ' |
Issuance of common stock for debt | ' | 74,091 | ' |
Issuance of common stock for services | ' | 1,750 | ' |
Issuances of convertible preferred stock, net | ' | 20,000 | ' |
Warrants returned to equity upon stock issued for debt | ' | 17,035 | ' |
Preferred stock dividends | -32,390 | -30,851 | -16,956 |
Balance | -4,782,787 | -4,127,295 | -4,103,462 |
Other Employee Contract Modification [Member] | Additional Paid-in Capital [Member] | ' | ' | ' |
Forgiveness of accrued expenses – related party | ' | 411,111 | ' |
Other Employee Contract Modification [Member] | ' | ' | ' |
Forgiveness of accrued expenses – related party | ' | 411,111 | ' |
Preferred Stock [Member] | ' | ' | ' |
Balance | ' | 17 | ' |
Balance (in Shares) | ' | 1,700 | ' |
Issuance of preferred stock for debt/dividends | ' | 14 | ' |
Issuance of preferred stock for debt/dividends (in Shares) | ' | 1,339 | ' |
Issuances of convertible preferred stock, net | ' | 2 | ' |
Issuances of convertible preferred stock, net (in Shares) | ' | 223 | ' |
Balance | 33 | 33 | ' |
Balance (in Shares) | 3,262 | 3,262 | ' |
Common Stock [Member] | ' | ' | ' |
Balance | 735,549 | 715,598 | ' |
Balance (in Shares) | 73,554,897 | 71,559,789 | ' |
Stock repurchase-debt settlement agreement | -2,639 | ' | ' |
Stock repurchase-debt settlement agreement (in Shares) | -263,889 | ' | ' |
Issuance of common stock for debt | ' | 19,451 | ' |
Issuance of common stock for debt (in Shares) | ' | 1,945,108 | ' |
Issuance of common stock for services | ' | 500 | ' |
Issuance of common stock for services (in Shares) | ' | 50,000 | ' |
Balance | 732,910 | 735,549 | ' |
Balance (in Shares) | 73,291,008 | 73,554,897 | ' |
Additional Paid-in Capital [Member] | ' | ' | ' |
Balance | 31,966,377 | 31,328,479 | ' |
Stock repurchase-debt settlement agreement | 2,139 | ' | ' |
Issuance of preferred stock for debt/dividends | ' | 133,864 | ' |
Issuance of common stock for debt | ' | 54,640 | ' |
Issuance of common stock for services | ' | 1,250 | ' |
Issuances of convertible preferred stock, net | ' | 19,998 | ' |
Warrants returned to equity upon stock issued for debt | ' | 17,035 | ' |
Balance | 31,968,516 | 31,966,377 | ' |
Retained Earnings [Member] | ' | ' | ' |
Balance | -36,829,254 | -36,147,556 | ' |
Net income | -622,602 | -650,847 | ' |
Preferred stock dividends | -32,390 | -30,851 | ' |
Balance | ($37,484,246) | ($36,829,254) | ' |
Statements_of_Stockholders_Def1
Statements of Stockholders’ Deficit (Parentheticals) (Additional Paid-in Capital [Member], USD $) | 12 Months Ended |
Dec. 31, 2012 | |
Issuance Of Preferred Stock For Dividends [Member] | ' |
Issuance price | $100 |
Issuance Of Common Stock For Debt [Member] | Minimum [Member] | ' |
Issuance price | $0.02 |
Issuance Of Common Stock For Debt [Member] | Maximum [Member] | ' |
Issuance price | $0.02 |
Issuance Of Common Stock For Services And Salaries [Member] | Minimum [Member] | ' |
Issuance price | $0.04 |
Issuance Of Convertible Preferred Stock Net [Member] | ' |
Issuance price | $100 |
Statements_of_Cash_Flows
Statements of Cash Flows (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Net loss | ($622,602) | ($650,847) |
Adjustments to reconcile net loss to net cash used in operating activities: | ' | ' |
Depreciation and amortization | 16,120 | 15,572 |
Common stock issued for salaries and services | ' | 1,750 |
Change in fair value of derivative liabilities | -4,217 | -44,096 |
Amortization of debt discount | ' | 21,467 |
Gain on conversion of debt | ' | -15,220 |
Debt Forgiveness Income | -42,702 | ' |
Changes in operating assets and liabilities: | ' | ' |
Prepaid expense and other current assets | -48,279 | -7,086 |
Accounts payable and accrued expenses | -61,797 | 78,870 |
Accrued interest – related parties | 99,229 | 110,148 |
Net cash used in operating activities | -664,248 | -489,442 |
Cash flows from Investing Activities | ' | ' |
Investment in patents | -15,059 | -4,074 |
Net cash used in investing activities | -15,059 | -4,074 |
Cash flows from Financing Activities | ' | ' |
Payments on notes payable | ' | -70,000 |
Proceeds from notes payable related party | 765,835 | 557,958 |
Payments on notes payable related party | -86,750 | -10,000 |
Issuance of convertible preferred stock for cash | ' | 20,000 |
Purchase and cancellation of treasury stock | -500 | ' |
Net cash provided by financing activities | 678,585 | 497,958 |
Net change in cash | -722 | 4,442 |
Cash and cash equivalents at beginning of period | 7,261 | 2,819 |
Cash and cash equivalents at end of period | 6,539 | 7,261 |
Supplemental Cash Flow Information | ' | ' |
Cash paid for interest | 4,137 | 6,081 |
Cash paid for income taxes | ' | ' |
Non-Cash Transactions | ' | ' |
Common stock issued for convertible debt | ' | 74,091 |
Preferred stock issued for notes payable related party and accrued interest (in Shares) | ' | 110,300 |
Preferred stock issued for accrued dividends and interest | ' | 23,578 |
Reclassification of derivative liability to permanent equity | ' | 17,035 |
Forgiveness of accrued salaries | ' | 411,111 |
Issuance of note payable related party for accrued salaries | ' | $100,000 |
Note_1_Organization_and_Summar
Note 1 - Organization and Summary of Significant Accounting Policies | 12 Months Ended | ||
Dec. 31, 2013 | |||
Accounting Policies [Abstract] | ' | ||
Organization, Consolidation, Basis of Presentation, Business Description and Accounting Policies [Text Block] | ' | ||
1. Organization and Summary of Significant Accounting Policies | |||
Organization and Business | |||
Amarillo Biosciences, Inc. (the "Company” or “AMARQ” or “Amarillo” or “ABI”), a Texas corporation formed in 1984, is engaged in developing biologics for the treatment of human and animal diseases. The Company’s current focus is research aimed at the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon alpha that is administered in a proprietary low dose oral form. | |||
Going Concern | |||
These financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. Losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability. | |||
The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty. | |||
There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern. | |||
Current Status | |||
On October 31, 2013, Amarillo Biosciences, Inc., (“ABI”) filed a voluntary petition in the Northern District of Texas, for protection under Chapter 11 of Title 11 of the U.S. Bankruptcy code. The purpose of the filing was to give the Company time to restructure organizationally and financially. To date, ABI remains in Chapter 11 Bankruptcy. The Company has been in contact with its creditors. At the time of the filing, the Company had $101,089 of assets and $4,787,127 of liabilities. There were two secured creditors, one unsecured priority claim, and thirty-nine (39) unsecured non-priority creditors with which ABI is aware. The prescribed meeting of creditors and deadlines (also known as the 341 Hearing) was properly noticed and subsequently held on December 10, 2013, at 10:15 A.M. No creditors’ committee was formed. On or about March 6, 2014, an Official Committee of Equity Holders was appointed by the U.S. Trustee for Region 6. To date, no action has been taken by that committee. The Company filed its Plan of Reorganization and Disclosure Statement on February 27, 2014. There is a hearing to consider approval of the Company’s Disclosure Statement on Thursday, March 27, 2014 at 2:00 P.M. | |||
Fair Value of Financial Instruments | |||
Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not to measure any eligible items using the fair value option. Consistent with Fair Value Measurement Topic of the FASB ASC, we implemented guidelines relating to the disclosure of our methodology for periodic measurement of our assets and liabilities recorded at fair market value. | |||
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: | |||
● | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; | ||
● | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and | ||
● | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. | ||
Our Level 1 assets and liabilities primarily include our cash and cash equivalents. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. The carrying amounts of accounts receivable, accounts payable, accrued liabilities, and notes payable approximate fair value due to the immediate or short-term maturities of these financial instruments. Our Level 2 liabilities consist of derivative liabilities. These are valued using observable inputs from readily available pricing sources for similar liabilities in active markets. | |||
Stock-Based Compensation | |||
Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation, for stock and stock options awarded in return for services rendered. The expense is measured at the grant-date fair value of the award and recognized as compensation expense on a straight-line basis over the service period, which is the vesting period. The Company estimates forfeitures that it expects will occur and records expense based upon the number of awards expected to vest. | |||
During fiscal years ended December 31, 2013 and 2012, no stock compensation was awarded. | |||
Cash and Cash Equivalents | |||
The Company classifies investments as cash equivalents if the original maturity of an investment is three months or less. | |||
Allowance for Doubtful Accounts | |||
The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to uncollectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company had no material accounts receivable and no allowance at December 31, 2013 and 2012. During 2013, the Company wrote off the existing uncollectible accounts receivable in the amount of $182. | |||
Inventory | |||
Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company continually assesses the appropriateness of inventory valuations giving consideration to slow-moving, non-saleable, out-of-date or close-dated inventory. As of December 31, 2013 and 2012 the Company had $184 and $1,058, respectively, of inventory included in other current assets. | |||
Property and Equipment | |||
Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two to seven year estimated useful lives of the assets. | |||
Patents and Patent Expenditures | |||
AMARQ holds patent license agreements and holds patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 to 20 year life of the patent. The Company continually evaluates the amortization period and carrying basis of patents to determine whether subsequent events and circumstances warrant a revised estimated useful life or impairment in value. To date, no such impairment has occurred. To the extent such events or circumstances occur that could affect the recoverability of our patents, we may incur charges for impairment in the future. | |||
Long-lived Assets | |||
Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No impairment losses have been recorded since inception. | |||
Income Taxes | |||
The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized. | |||
Revenue Recognition | |||
Dietary supplement and interferon sales | |||
Revenues for the dietary supplement and interferon sales are recognized when an arrangement exists, the price is fixed and it has been determined that collectability is reasonably assured. This generally occurs at the point when the goods are shipped to the customer. | |||
Sublicense fee revenue | |||
Sublicense revenue is calculated based on fees relating to a license. Amarillo recognizes revenue on these sublicense fees in the month the revenue is generated by the licensee. | |||
Royalty revenue | |||
Royalty revenue is calculated based on royalty fees as a percent of net sales relating to a license. Amarillo recognizes revenue on these royalty payments in the year the revenue is generated by the licensee. HBL reported no sales of Bimron to Bio Vet for 2013 and 2012. | |||
Research and Development | |||
Research and development costs are expensed as incurred. | |||
Use of Estimates | |||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |||
The most significant estimates are the assumptions used in the valuation models to determine the fair value of stock-based compensation and the fair value of the derivative liability. | |||
Basic and Diluted Net Loss Per Share | |||
Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. In 2013 and 2012, options and warrants outstanding were antidilutive and not included in the calculation of fully diluted net loss per share. | |||
Concentration of Credit Risk | |||
Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. | |||
The Company has cash balances in a single financial institution which, from time to time, exceed the federally insured limit of $250,000. No loss has been incurred related to this concentration of cash. | |||
Other Concentrations | |||
On March 13, 1992, we entered into a Joint Development and Manufacturing/Supply Agreement with HBL (the “Development Agreement”). As of February 1, 2012, HBL began operating under the name Hayashibara Company, Ltd. (“HBC”) as a wholly-owned subsidiary of Nagase Corporation. In correspondence received April 23, 2012, HBC informed us that they had decided to permanently halt production of interferon. Subsequently, ABI was informed that HBC was preparing a letter of notification that the Development Agreement would be terminated. On September 23, 2012, the expected notification letter was received, and the Development Agreement was officially terminated as of December 22, 2012. | |||
On October 26, 2006, we entered into a Supply Agreement Anhydrous Crystalline Maltose with HBL (the “ACM Supply Agreement”). In correspondence received September 23, 2013, HBC informed us that, in accordance with Section 3 of the ACM Supply Agreement, it would be terminated as of October 26, 2013. | |||
Among other things, the Development Agreement provided us and our sub-licensees with a source of natural human interferon alpha for use in the Company’s interferon alpha-containing products. Termination of the Development Agreement leaves the Company without a current source of interferon with which to conduct clinical trials or to supply its sub-licensees. The Company is exploring its options and is talking with alternate suppliers of interferon. | |||
Recent Accounting Pronouncements | |||
Management does not anticipate that any recently issued but not yet effective accounting pronouncements will materially impact the Company’s financial condition. |
Note_2_Property_Equipment_and_
Note 2 - Property, Equipment and Software, net | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Property, Plant and Equipment [Abstract] | ' | ||||||||
Property, Plant and Equipment Disclosure [Text Block] | ' | ||||||||
2. Property, Equipment and Software, net | |||||||||
Property, equipment and software are stated at cost less accumulated depreciation and consist of the following at December 31, 2013 and 2012: | |||||||||
2013 | 2012 | ||||||||
Furniture and equipment | $ | 38,221 | $ | 38,221 | |||||
Software | 8,012 | 8,012 | |||||||
46,233 | 46,233 | ||||||||
Less: accumulated depreciation | (46,233 | ) | (46,233 | ) | |||||
Property, equipment and software, net | $ | - | $ | - | |||||
Depreciation expense amounted to $0 and $42 for the years ended December 31, 2013 and 2012, respectively. |
Note_3_Patents_net
Note 3 - Patents, net | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ||||||||
Goodwill and Intangible Assets Disclosure [Text Block] | ' | ||||||||
3. Patents, net | |||||||||
Patents are stated at cost less accumulated amortization and consist of the following at December 31, 2013 and 2012: | |||||||||
2013 | 2012 | ||||||||
Patents | $ | 173,488 | $ | 158,429 | |||||
Less: accumulated amortization | (80,449 | ) | (64,329 | ) | |||||
Patents, net | $ | 93,039 | $ | 94,100 | |||||
Amortization expense amounted to $16,120 and $15,530 for the years ended December 31, 2013 and 2012, respectively. | |||||||||
Estimated future amortization expense is as follows: | |||||||||
2014 | $ | 16,376 | |||||||
2015 | 16,376 | ||||||||
2016 | 12,525 | ||||||||
2017 | 12,525 | ||||||||
2018 | 11,162 | ||||||||
thereafter | 24,075 | ||||||||
Total expense | $ | 93,039 | |||||||
Note_4_Notes_Payable
Note 4 - Notes Payable | 12 Months Ended |
Dec. 31, 2013 | |
Debt Disclosure [Abstract] | ' |
Debt Disclosure [Text Block] | ' |
4. Notes Payable | |
Related Party | |
The Company has two $1,000,000 notes payable under an unsecured loan agreement with HBL dated July 22, 1999. The annual interest rate on unpaid principal from the date of each respective note is 4.5 percent, with accrued interest being payable at the maturity. One $1,000,000 note was payable on or before June 3, 2008. The other $1,000,000 note was payable on or before August 28, 2010. Although we are currently in default of the notes, HBL has not demanded payment. During 2008, the Company paid HBL $200,000 of interest on these notes. The principal and accrued interest through October 31, 2013 is listed on Schedule F of the Summary of Schedules filed by ABI with the United States Bankruptcy Court. Schedule F is the List of Unsecured Non-priority (Creditors’) Claims. The claim is also scheduled in Class Four – General Unsecured Creditors of the Plan of Reorganization in the amount of $3,006,752.88. | |
In 2010, the Company entered into a verbal agreement with Paul Tibbits, a Director, to purchase 12,000,000 warrants held by him for $200,000. The agreement included interest, using the Applicable Federal Rate (“AFR”) at 0.43% per annum, with no stated maturity date, and no collateral. A promissory note in the amount of $200,000 to Paul Tibbits was executed on January 10, 2011. This note was in default at year end and now accrues interest at the default rate of 10% per annum. The note was still outstanding as of December 31, 2013. This debt is listed on Schedule F of the Summary of Schedules filed by the Company with the United States Bankruptcy Court. Schedule F is the list of Unsecured Non-priority (Creditors’) Claims. The Claim is also scheduled in Class Four – General Unsecured Creditors of the Plan of Reorganization. The debt includes $200,000 of principal and $35,055.56 of pre-petition interest accrued through October 31, 2013. | |
As of February 8, 2012, the Company had promissory notes totaling $85,000 to Paul Tibbits. The principal of the debt, $85,000, was paid to Mr. Tibbits with 850 shares of the Company’s Series 2010-A 10% Convertible Preferred Stock Additionally, on February 8, 2012, the Company paid $48,878 to Mr. Tibbits for unpaid Preferred Dividends, interest on Notes Payable, and interest on unpaid Preferred Dividends. This amount was paid with 489 shares of the Company’s Series 2010-A 10% Convertible Preferred Stock. The total conveyance of preferred shares on February 8, 2012, was 1,339. The Company accrued the following Dividends on Preferred Stock for Mr. Tibbits in each of the following time periods: February 9, 2012 through December 31, 2012, $30,851; January 1, 2013 through October 31, 2013, $26,992; and November 1, 2013 through December 31, 2013, $5,398. The Company also accrued interest on unpaid dividends for the same periods in 2012 and 2013 in the respective amounts $4,628 and $1,458. Interest on the $200,000 Note Payable was also accrued for February 8, 2012 through December 31, 2012, $18,167, and for January 1, 2013, through October 31, 2013, $16,889. | |
The Yang Group transferred cash to ABI through Dr. Stephen Chen, ABI CEO, and subsequently wired the funds to the Company for working capital loans to be used for operations; total cash received from The Yang Group through Dr. Chen for 2012 was $547,958. During 2013 through July 19, 2013, cash received through Dr. Chen was $428,835. The advances were short term, without due dates, and with no stated interest rates or any other terms. | |
On July 19, 2013, the unsecured funds advanced from The Yang Group through Dr. Chen ($976,793), were reduced to a promissory note made payable by Amarillo Biosciences, Inc. to the Yang Group, The note was a demand note with no certain due date with an annual interest rate of 23/100 of one percent (.23%) due on unpaid principal from the date of funding. The interest rate was based on the Applicable Federal Rate (AFR) in force for the month in which the note was executed. The note carried a 10% annual interest rate on material, unpaid amounts. There was no penalty for prepayment of outstanding amounts. | |
On July 25, 2013, The Yang Group began advancing funds under a new promissory note which is secured by substantially all of the assets of the Company. The note is a revolving/advancing note for $300,000 or so much thereof as may from time to time have been advanced. The annual interest rate as to each advance thereunder, is at the short term Applicable Federal Rate (AFR) determined under Section 1274(d) of the Internal Revenue Code of 1986, for the month in which such advance was received. As of December 31, 2013, $280,000 had been advanced under the secured note. | |
An order of the Bankruptcy Court approved a Post-Petition Financing Facility on January 15, 2014. The Facility is an unsecured, priority basis financing facility approving up to $285,000 of funds to be advanced as needed. To date, $164,972 has been advanced under the Post-Petition Financing Facility. The source of funds under the Facility continues to be The Yang Group. | |
Subsequent to the balance sheet date of December 31, 2013, $107,972 has been received through March 29, 2014. These funds were received as explained in the preceding paragraph. | |
We have a line of credit with Wells Fargo for $20,000, with an interest rate of prime rate plus 6.75 percent. There was an outstanding balance of $18,376 on October 31, 2013, when the Chapter 11 Petition was filed. This debt is listed on Schedule F of the Summary of Schedules filed by the Company with the United States Bankruptcy Court. Schedule F is the list of Unsecured Non-priority (Creditors’) Claims. The Claim is also scheduled in Class Four – General Unsecured Creditors of the Plan of Reorganization. This debt is also included on the December 31, 2013 Balance Sheet and the outstanding balance of $18,376 is included in accounts payable and accrued expenses. |
Note_5_License_Sublicense_Manu
Note 5 - License, Sublicense, Manufacturing, Research and Supply Agreements | 12 Months Ended |
Dec. 31, 2013 | |
License Sublicense Manufacturing Research And Supply Agreements [Abstract] | ' |
License Sublicense Manufacturing Research And Supply Agreements [Text Block] | ' |
5. License, Sublicense, Manufacturing, Research and Supply Agreements | |
Manufacturing and Supply Agreements: | |
The Company was a party to the following manufacturing and supply agreements at December 31, 2013. | |
On March 13, 1992, we entered into a Joint Development and Manufacturing/Supply Agreement with HBL (the “Development Agreement”). As of February 1, 2012, HBL began operating under the name Hayashibara Company, Ltd. (“HBC”) as a wholly-owned subsidiary of Nagase Corporation. On September 23, 2012, a 90-day notice of termination letter was received, and the Development Agreement was officially terminated as of December 22, 2012. | |
Among other things, the Development Agreement provided ABI with a source of natural human interferon alpha for use in the Company’s interferon alpha-containing products. Termination of the Development Agreement leaves the Company without a current source of interferon with which to conduct clinical trials and ultimately commercialize a product. The Company is exploring its options and is talking with alternate suppliers of interferon. | |
On October 26, 2006, we entered into a Supply Agreement Anhydrous Crystalline Maltose with HBL (the “ACM Supply Agreement”). In correspondence received September 23, 2013, HBC informed us that, in accordance with Section 3 of the ACM Supply Agreement, it would be terminated as of October 26, 2013. | |
Historically, the research and development was conducted by ABI using a unique form of natural human interferon supplied by HBL. This interferon no longer provides a competitive edge insomuch as the industry as a whole is rapidly moving toward the use of recombinant interferon rather than natural human interferon. ABI’s thirty years of data has been generated from the numerous studies performed using natural human interferon. Since human interferon is virtually impossible to obtain, those studies will have to be repeated using recombinant interferon. Repeating the studies will be both costly and time consuming. While the pharmaceutical industry is creating and marketing new and effective anti-viral medications, ABI believes that there is still sufficient time to develop and commercialize low dose interferon for treatment of such diseases as Influenza, Chronic Cough in COPD, Hepatitis B, C, and D, and Thrombocytopenia caused by other diseases and as a side effect of treatment of other diseases. | |
Strategic Alliance with CytoPharm | |
On May 15, 2013, the Company entered into a CIT Patents Agreement with CytoPharm, Inc. (“CP”) a former licensee for oral IFN technology in Taiwan and China. This agreement establishes the ownership, inventorship, prosecution, maintenance, use and commercialization of a patent regarding treatment of thrombocytopenia with oral IFN that developed out of a study conducted by CP under a previous License and Supply Agreement. | |
Strategic Alliance with Bumimedic | |
In January 2006, a license and distribution agreement was executed with Bumimedic (Malaysia) Sdn. Bhd, a Malaysian pharmaceutical company that is a part of the Antah HealthCare Group, to market the Company’s low-dose interferon (natural human IFN) in Malaysia. Given the problems associated with the natural human interferon supply, it is likely that the agreement with Bumimedic will be terminated as the Company can no longer supply Bumimedic with natural human IFN produced by Hayashibara. Once the problems associated with the interferon supply are solved, the Company will most likely endeavor to enter into another such agreement with Bumimedic. | |
Strategic Alliance with Intas Pharmaceuticals | |
On January 7, 2010, the Company entered into a License and Supply Agreement with Intas Pharmaceuticals Ltd., an India-based pharmaceutical company with three decades of experience in the healthcare industry and a global presence in 42 countries worldwide. Given the problems associated with the natural human interferon supply, it is likely that the agreement with Intas will be terminated as the Company can no longer supply them with natural human IFN produced by Hayashibara. Once the problems associated with the interferon supply are solved, the Company will most likely endeavor to enter into another such agreement with Intas Pharmaceuticals. | |
License and Sublicense Agreements: | |
The Company holds patent rights for which the Company has paid certain license fees under a license agreement with Texas A&M University System. Under this agreement, the Company will pay the licensor a portion of any sublicense fee received by the Company with respect to the manufacturing, use or sale of a licensed product, as well as a royalty fee based on the net selling price of licensed products, subject to a minimum annual royalty. | |
The minimum cash royalty owed to Texas A&M University System as of December 31, 2013 is $22,500. | |
Even though the license agreement with HBL has been terminated, a total of $78,360 in sublicense fees are owed to HBL based on sublicense fee income earned by the Company during 2008 and 2009 and are included in accrued expenses – related party. There were no sublicense fees due to HBL for 2012 or 2013. | |
The Company has also entered into various sublicense agreements under which the Company is entitled to receive royalties based on the net sales value of licensed products. However, given the termination of the Development Agreement with HBL, some of these sublicense agreements have been canceled, and it is likely that the rest will be terminated in the near future. | |
Research Agreements: | |
The Company currently has no ongoing studies so there are no obligations to pay third parties in 2014 for expenses related to clinical studies. |
Note_6_Common_Stock
Note 6 - Common Stock | 12 Months Ended | |||||||||||||
Dec. 31, 2013 | ||||||||||||||
Stockholders' Equity Note [Abstract] | ' | |||||||||||||
Stockholders' Equity Note Disclosure [Text Block] | ' | |||||||||||||
6. Common Stock | ||||||||||||||
The Company has 100,000,000 shares of voting common shares authorized for issuance. On December 31, 2013, the Company had 80,593,300 shares of common stock outstanding and reserved for issuance upon exercise of options and warrants and conversion of preferred stock. The Company issued common stock in 2013 and 2012 as follows: | ||||||||||||||
Common Stock Issued in 2013 | Shares | Issue Price | Net Price | |||||||||||
None | - | $ | - | $ | - | |||||||||
Total Common Stock Issued in 2013 | - | $ | - | $ | - | |||||||||
Common Stock Issued in 2012 | Shares | Issue Price | Net Price | |||||||||||
Directors, officers, consultants plan– services | 50,000 | $0.04 | $ | 1,750 | ||||||||||
Debt conversion – cashless | 1,945,108 | $0.02 | - | 0.0208 | 74,091 | |||||||||
Total Common Stock Issued in 2012 | 1,995,108 | $0.02 | - | 0.035 | $ | 75,841 | ||||||||
During the years ended December 31, 2013 and December 31, 2012, there were no finder’s fees paid related to private placements of stock. | ||||||||||||||
We have not paid any dividends to our common stock shareholders to date, and have no plans to do so in the immediate future. | ||||||||||||||
We use the services of American Stock Transfer and Trust Company as our transfer agent. |
Note_7_Preferred_Stock
Note 7 - Preferred Stock | 12 Months Ended |
Dec. 31, 2013 | |
Disclosure Text Block Supplement [Abstract] | ' |
Preferred Stock [Text Block] | ' |
7. Preferred Stock | |
The Company has 10,000,000 shares of preferred stock authorized for issuance which is issuable in series. | |
The Board of directors authorized the issuance of up to 10,000 shares of Series 2010-A 10% Convertible Preferred Stock on July 29, 2010. Each preferred share is convertible into 1,000 common shares ($100 stated value per share divided by $0.10). Dividends are payable quarterly at 10% per annum in cash or stock at the option of the preferred stock Holder. Stock dividend payments are valued at the higher of $0.10 per share of common stock or the average of the two highest volume weighted average closing prices for the 5 consecutive trading days ending on the trading day that is immediately prior to the dividend payment date. During 2011, a total of 200 shares of Series 2010-A 10% Convertible Preferred Stock were issued to a Director. The preferred stock is convertible into 200,000 shares of restricted common stock. In 2011, the Company recorded $16,956 of dividends related to the 1,700 shares of preferred stock outstanding. Of this amount, $16,956 was unpaid as of December 31, 2011. During 2012, a total of 1,562 shares of Series 2010-A 10% Convertible Preferred Stock were issued to a Director. Of the 1,562 preferred shares issued, 223 were issued for cash of $20,000. The 1,339 shares were issued as payment for loan principal of $85,000 and interest on notes and dividends (previously payable from 2011) of $48,878. The preferred stock is convertible into 1,562,000 shares of restricted common stock. In 2013, the Company recorded $32,390 and in 2012, $30,851 of dividends related to the 3,262 shares of preferred stock outstanding. Of this amount, $63,241 was unpaid as of December 31, 2013. |
Note_8_Stock_Option_and_Stock_
Note 8 - Stock Option and Stock Plans | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | |||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Text Block] | ' | |||||||||||||||
8. Stock Option and Stock Plans | ||||||||||||||||
Stock Plans * | Issue Date Range | Total Shares Authorized | Shares Issued | Shares Remaining | ||||||||||||
2008 Stock Incentive Plan | 5/23/08 | – | 10/11/11 | 600,000 | 463,420 | 136,580 | ||||||||||
2008 Executive Officers Compensatory Stock Plan | 7/10/08 | – | 9/17/08 | 200,000 | 51,563 | 148,437 | ||||||||||
2008 Amended and Restated Directors, Officers and Consultants Stock Purchase Plan**** | 10/22/08 | – | 7/31/13 | 8,000,000 | 7,502,902 | 497,098 | ||||||||||
2009 Consultants Stock Grant Plan | 7/13/09 | – | 10/31/09 | 100,000 | 50,000 | 50,000 | ||||||||||
Non Stock Plan Issuances | 6/2/08 | – | 3/12/10 | 929,562 | 205,863 | 723,699 | ||||||||||
Stock Option Plans * | Issue Date Range | Total Options Authorized** | Options Issued | Options Remaining | ||||||||||||
2009A Officers, Directors, Employees and Consultants Nonqualified Stock Option Plan *** | 4/30/09 | – | 3/8/11 | 20,000,000 | 3,050,000 | 16,950,000 | ||||||||||
Non Stock Option Plan Issuances | 6/30/08 | – | 12/16/08 | 1,056,912 | 1,056,912 | 0 | ||||||||||
* The Board of Directors has approved all stock, stock option and stock warrant issuances. | ||||||||||||||||
** One option reserves one share of common stock. | ||||||||||||||||
*** This plan replaces and supersedes in their entirety the Company’s Outside Director and Advisor Stock Option Plan, as amended and restated as of May 11, 1999; the Company’s 1996 Employee’s Stock Option Plan, as amended and restated as of May 11, 1999; and the Company’s First Amended 2006 Employee’s Stock Option and Stock Bonus Plan; provided however, that options already issued and outstanding under said superseded plans shall continue to be outstanding and exercisable in accordance with their terms, as such may have been extended or re-priced from time to time, and the terms of any applicable option agreements entered into between the Company and the Optionee. | ||||||||||||||||
**** On July 12, 2013, ABI and PAN Consulting, Ltd. entered into and executed a Settlement Agreement and Release whereby ABI paid $5,500 in full and final settlement of any and all claims held or asserted by PAN Consulting, Ltd. and PAN Consulting, Ltd. agreed to endorse and deliver to ABI any and all stock certificates evidencing an aggregate of 263,889 shares of ABI common stock. The terms of the agreement also included termination of the contract executed in 2006 by the parties. The shares were returned to the Plan. |
Note_9_Stock_Options_and_Warra
Note 9 - Stock Options and Warrants | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Stock Option And Warrants [Abstract] | ' | |||||||||||||||||||
Stock Option And Warrants [Text Block] | ' | |||||||||||||||||||
9. Stock Options and Warrants | ||||||||||||||||||||
Stock Options: | ||||||||||||||||||||
During 2013 and 2012, no options were issued to consultants. | ||||||||||||||||||||
Directors, officers and consultants exercised no options in 2013 or 2012. | ||||||||||||||||||||
Stock option activity for the years ended December 31, 2012 and December 31, 2013 are summarized as follows: | ||||||||||||||||||||
Shares | Weighted | Weighted Average Remaining Contractual Life (in Years) | Grant Date Fair Value | |||||||||||||||||
Average | ||||||||||||||||||||
Exercise Price | ||||||||||||||||||||
Outstanding at December 31, 2011 | 3,641,792 | $ | 0.07 | 3.84 | $ | 238,850 | ||||||||||||||
Options granted | - | - | - | - | ||||||||||||||||
Options exercised | - | - | - | - | ||||||||||||||||
Options cancelled/expired | (1,789,000 | ) | (0.08 | ) | - | (134,167 | ) | |||||||||||||
Outstanding at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Vested at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Exercisable at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Outstanding at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Options granted | - | - | - | - | ||||||||||||||||
Options exercised | - | - | - | - | ||||||||||||||||
Options cancelled/expired | (100,000 | ) | 0.08 | - | (7,280 | ) | ||||||||||||||
Outstanding at December 31, 2013 | 1,752,792 | $ | 0.06 | 2.41 | $ | 97,403 | ||||||||||||||
Vested at December 31, 2013 | 1,752,792 | $ | 0.06 | 2.41 | $ | 97,403 | ||||||||||||||
Outstanding at December 31, 2013 | 1,752,792 | $ | 0.06 | 2.41 | $ | 97,403 | ||||||||||||||
Options reserved for the director, employee and consultant stock option plan but not issued (16,950,000) are not included in the table above. This stock may be utilized for other purposes if not used for the plans. | ||||||||||||||||||||
Stock warrants: | ||||||||||||||||||||
On February 6, 2012, 724,487 warrants were issued as a result of having issued 693,069 shares for debt to Hope Capital at $0.0202 per share The Base Share Price for this dilutive issuance was $0.0202 per share. ABI sent a Dilutive Issuance Notice to Warrant Strategies, Inc. on February 6, 2012. The notice was sent pursuant to the Series A Common Stock Purchase Warrant dated June 16, 2009, Section 3(b), “…the Exercise Price shall be reduced to equal the Base Share Price and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise price issuable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment.” | ||||||||||||||||||||
ABI issued a new Purchase Warrant dated February 6, 2012 reflecting the new Warrant Share amount of 2,217,817 shares (724,487 additional warrants plus the 1,493,330 existing warrants) and an adjusted Exercise Price of $0.0202 per share. The new warrant was sent to Warrant Strategies, Inc. and return of the old warrant was requested. | ||||||||||||||||||||
No warrants were exercised in 2013 or 2012. | ||||||||||||||||||||
A summary of the Company's stock warrant activity and related information for the years ended December 31, 2013 and December 31, 2012 is as follows: | ||||||||||||||||||||
2013 | 2012 | |||||||||||||||||||
Warrants | Price Range | Warrants | Price Range | |||||||||||||||||
Outstanding Beg. of Year | 6,642,317 | $ | 0.0202 | - | 0.1 | 8,730,190 | $ | 0.03 | - | 0.1 | ||||||||||
Granted | - | - | 724,487 | 0.0202 | ||||||||||||||||
Cancelled/Expired | (4,354,817 | ) | $ | -0.0202 | - | -0.1 | (2,812,360 | ) | -0.1 | |||||||||||
Exercised | - | - | - | - | ||||||||||||||||
Outstanding End of Year | 2,287,500 | $ | 0.03 | - | 0.04 | 6,642,317 | $ | 0.0202 | - | 0.1 | ||||||||||
Exercisable End of Year | 2,287,500 | $ | 0.03 | - | 0.04 | 6,642,317 | $ | 0.0202 | - | 0.1 | ||||||||||
The weighted-average remaining contractual life of the warrants outstanding at December 31, 2013 is 0.99 years. | ||||||||||||||||||||
Derivative Liabilities: | ||||||||||||||||||||
On February 6, 2012, Amarillo Biosciences, Inc. issued 724,487 warrants as a result of having issued 693,069 shares for debt to Hope Capital at $0.0202 per share The Base Share Price for this dilutive issuance was $0.0202 per share. ABI sent a Dilutive Issuance Notice to Warrant Strategies, Inc. on February 6, 2012. The notice was sent pursuant to the Series A Common Stock Purchase Warrant dated June 16, 2009, Section 3(b), “…the Exercise Price shall be reduced to equal the Base Share Price and the number of Warrant Shares issuable hereunder shall be increased such that the aggregate Exercise price issuable hereunder, after taking into account the decrease in the Exercise Price, shall be equal to the aggregate Exercise Price prior to such adjustment.” | ||||||||||||||||||||
ABI issued a new Purchase Warrant dated February 6, 2012 reflecting the new Warrant Share amount of 2,217,817 shares (724,487 additional warrants plus the 1,493,330 existing warrants) and an adjusted Exercise Price of $0.0202 per share. The new warrant was sent to Warrant Strategies, Inc. and return of the old warrant was requested. | ||||||||||||||||||||
The fair value of warrants with embedded derivative feature was estimated at December 31, 2012 with the binomial Black-Scholes option-pricing model using the following assumptions: probability of anti-dilution ratchet of 75%; a probable reset share price of $0.0155; dividend yield 0.0%; expected volatility of 234.76%, risk-free interest rate of 0.14% and expected life of approximately 0.02 years (the remaining term of the warrants). The fair value of the 2,217,817 outstanding warrants was $4,217. | ||||||||||||||||||||
During the year ended December 31, 2012, Hope Capital, Inc. exercised its right to convert debt into shares of ABI Common Stock. The embedded conversion features in the debt conversion and redemption features were accounted for as a derivative liability. The debt also included warrants which were valued as a liability and discount to the note, due to the unknown number of shares to be issued upon conversion of the debt, causing a lack of sufficient authorized shares to be available to settle the warrants. The derivative liabilities were marked-to-market each quarter with the change in fair value recorded in the income statement. At each respective conversion date, the derivative liabilities were remeasured with the changes in fair value recorded to the income statement. At full conversion of the debt the warrants were no longer deemed to be a liability and were returned to equity for $17,035. | ||||||||||||||||||||
Net derivative gain for 2013 was $4,217. In 2012, the derivative gain was $44,096. |
Note_10_Income_Taxes
Note 10 - Income Taxes | 12 Months Ended |
Dec. 31, 2013 | |
Income Tax Disclosure [Abstract] | ' |
Income Tax Disclosure [Text Block] | ' |
10. Income Taxes | |
Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes. The Company’s deferred tax asset of approximately $7,742,000 and $7,540,000 at December 31, 2013 and 2012, respectively, was subject to a valuation allowance of $7,742,000 and $7,540,000 at December 31, 2013 and 2012, respectively, because of uncertainty regarding the Company’s ability to realize future tax benefits associated with the deferred tax assets. Deferred tax assets were comprised primarily of net operating loss carryovers under the cash method of accounting used by the Company for federal income tax reporting. The valuation allowance increased by $202,000 in 2013 and decreased by $430,000 in 2012, due to the changes in the Company’s net operating loss carryover amounts. | |
At December 31, 2012, the Company has net operating loss carryforwards of approximately $22,176,000 for federal income tax purposes expiring in 2013 through 2032. At December 31, 2013, the Company has net operating loss carryforwards of approximately $22,770,000 for federal income tax purposes expiring in 2014 through 2033.The ability of the Company to utilize these carryforwards may be limited should changes in stockholder ownership occur. | |
The difference between the reported income tax provision and the benefit normally expected by applying the statutory rate to the loss before income taxes results from the change during 2013 and 2012 of the deferred tax asset valuation allowance. As a result, the reported effective tax rate is 0%. |
Note_11_Commitments_and_Contin
Note 11 - Commitments and Contingencies | 12 Months Ended |
Dec. 31, 2013 | |
Commitments and Contingencies Disclosure [Abstract] | ' |
Commitments and Contingencies Disclosure [Text Block] | ' |
11. Commitments and Contingencies | |
Delinquent payroll | |
During 2011 and 2012, the Company curtailed payment of salaries payable to senior management of the Company. As of December 31, 2012, approximately $113,222 of unpaid salaries due to senior management of the Company is included in accounts payable and accrued expenses for $13,222 and notes payable-related parties for $100,000. While the significance of the amounts owed to senior management subjects the Company to the risk of resignation by these officers, as well as possible litigation, the risk was mitigated by the retirement of Dr. Joseph M. Cummins, his waiving of any and all claim to back salary of $267,811 and other benefits, and a compromise and settlement agreement between Martin Cummins and the Company waiving claims to back salary of $143,300. The $113,222 still owed at December 31, 2012, consisted of a $100,000 Note Payable to Martin Cummins for the balance of the back salary and $13,222 to another officer. At December 31, 2013, the amount still owed to Martin Cummins was $13,250. This amount was treated as an Unsecured Non-Priority Debt with Martin Cummins as the Creditor. The Debt was included in Schedule F of the Summary of Schedules filed with the Bankruptcy Court and included with Class Four Creditors. | |
Lease commitment | |
Our executive and administrative offices are located at 4134 Business Park Drive, Amarillo, Texas in a 1,800 square-foot facility rented by the Company. The lease expires on June 30, 2014 and our monthly rent is $1,045 per month. We believe that the facilities are well maintained and generally suitable and adequate for our current and projected operating needs. This lease was affirmed by the Company as shown in the Disclosure Statement filed February 21, 2014, and approved on March 27, 2014. | |
Minimum Royalties | |
The agreement with Texas A&M University requires the Company to make minimum annual royalty payments of $7,500 through 2019. | |
Clinical Trial Costs | |
The Company currently has no ongoing studies, so there are no obligations to pay third parties in 2013 for expenses related to clinical studies. | |
Litigation | |
The Company is not a party to any litigation and is not aware of any pending litigation or unasserted claims or assessments as of December 31, 2013. |
Note_12_Related_Party_Transact
Note 12 - Related Party Transactions | 12 Months Ended |
Dec. 31, 2013 | |
Related Party Transactions [Abstract] | ' |
Related Party Transactions Disclosure [Text Block] | ' |
12. Related Party Transactions | |
In the past the Company has relied significantly on HBL, a large shareholder of the Company, for a substantial portion of its capital requirements. | |
Although the Development Agreement was terminated by HBL as of December 22, 2012, the Company is obligated to pay HBL a percentage of sublicense fee income the Company received prior to that date. We owed $78,360 of accrued sublicense fees to HBL on December 31, 2013. | |
Prior to December 22, 2012, HBL was obligated to pay the Company an 8% royalty on sales of oral interferon in Japan. The Company recorded $0 of royalties in both 2013 and 2012 from HBL animal health sales of oral interferon. | |
Amendment #4 to the employment contract of Joseph M. Cummins (“Employee”) was entered into on May 19, 2012 by Employee and ABI (“Employer”). The amendment provides for the change in annual salary of Employee from $175,000 per year to $5,000 per month ($60,000 annually). Additionally, Employee releases Employer from any liability for payment of back salary or benefits (of any form) in the amount of $278,259. Further, the Company forgave an employee receivable of approximately $10,448 in connection with the amended employment agreement. The Amendment further states that term of the contract shall be through November 30, 2012. Commencing December 1, 2012 through November 30, 2014, the Employee will become a consultant for the monthly sum of $5,000. The Amendment was effective as of May 15, 2012 and was executed by Dr. Stephen T Chen, PhD, Chairman and CEO and Joseph M. Cummins, DVM, PhD, President and COO. This contract will be rejected as shown in the Disclosure Statement. | |
On October 31, 2012, ABI carried a liability for back salary owed Martin Cummins in the amount or $236,732. An agreement was reached between ABI and Martin Cummins wherein the parties agreed that claim to $136,732 was waived and forgiven by Martin Cummins, both parties agreed to execute a note payable for $100,000 which was not forgiven by Mr. Cummins and would be paid with a $40,000 down payment and a payout according to a schedule, and a new employment contract where Mr. Cummins was given ten months at $5,000 gross salary per month to be employed. Furthermore, both parties agreed to execute a mutual release of liability and Mr. Cummins agreed to return 879,000 ABI stock options. | |
All future transactions and loans between the Company and its officers, directors and 5% shareholders will be on terms no less favorable to the Company than could be obtained from independent third parties. There can be no assurance, however, that future transactions or arrangements between the Company and its affiliates will be advantageous, that conflicts of interest will not arise with respect thereto or that if conflicts do arise, that they will be resolved in favor of the Company. |
Note_13_Subsequent_Events
Note 13 - Subsequent Events | 12 Months Ended |
Dec. 31, 2013 | |
Subsequent Events [Abstract] | ' |
Subsequent Events [Text Block] | ' |
13. Subsequent Events | |
From January 1, 2014 through the date of this report $107,972 was received by the Company from The Yang Group through Dr. Stephen T. Chen. |
Accounting_Policies_by_Policy_
Accounting Policies, by Policy (Policies) | 12 Months Ended | ||
Dec. 31, 2013 | |||
Accounting Policies [Abstract] | ' | ||
Basis of Accounting [Text Block] | ' | ||
Organization and Business | |||
Amarillo Biosciences, Inc. (the "Company” or “AMARQ” or “Amarillo” or “ABI”), a Texas corporation formed in 1984, is engaged in developing biologics for the treatment of human and animal diseases | |||
Going Concern Note | 'Going ConcernThese financial statements have been prepared in accordance with United States generally accepted accounting principles, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company has not yet achieved operating income, and its operations are funded primarily from debt and equity financings. Losses are anticipated in the ongoing development of its business and there can be no assurance that the Company will be able to achieve or maintain profitability.The continuing operations of the Company and the recoverability of the carrying value of assets is dependent upon the ability of the Company to obtain necessary financing to fund its working capital requirements, and upon future profitable operations. The accompanying financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result from the outcome of this uncertainty.There can be no assurance that capital will be available as necessary to meet the Company's working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans, assuming those loans would be available, will increase the Company's liabilities and future cash commitments. If the Company is unable to obtain financing in the amounts and on terms deemed acceptable, the business and future success may be adversely affected and the Company may cease operations. These factors raise substantial doubt regarding our ability to continue as a going concern. | ||
Fair Value of Financial Instruments, Policy [Policy Text Block] | ' | ||
Fair Value of Financial Instruments | |||
Under the Financial Account Standards Board Accounting Standards Codification (“FASB ASC”), we are permitted to elect to measure financial instruments and certain other items at fair value, with the change in fair value recorded in earnings. We elected not to measure any eligible items using the fair value option. Consistent with Fair Value Measurement Topic of the FASB ASC, we implemented guidelines relating to the disclosure of our methodology for periodic measurement of our assets and liabilities recorded at fair market value. | |||
Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. A three-tier fair value hierarchy prioritizes the inputs used in measuring fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurements) and the lowest priority to unobservable inputs (level 3 measurements). These tiers include: | |||
● | Level 1, defined as observable inputs such as quoted prices for identical instruments in active markets; | ||
● | Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable such as quoted prices for similar instruments in active markets or quoted prices for identical or similar instruments in markets that are not active; and | ||
● | Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring an entity to develop its own assumptions, such as valuations derived from valuation techniques in which one more significant inputs or significant value drivers are unobservable. | ||
Our Level 1 assets and liabilities primarily include our cash and cash equivalents. Valuations are obtained from readily available pricing sources for market transactions involving identical assets or liabilities. The carrying amounts of accounts receivable, accounts payable, accrued liabilities, and notes payable approximate fair value due to the immediate or short-term maturities of these financial instruments. Our Level 2 liabilities consist of derivative liabilities. These are valued using observable inputs from readily available pricing sources for similar liabilities in active markets. | |||
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block] | ' | ||
Stock-Based Compensation | |||
Stock-based compensation expense is recorded in accordance with FASB ASC Topic 718, Compensation – Stock Compensation, for stock and stock options awarded in return for services rendered. The expense is measured at the grant-date fair value of the award and recognized as compensation expense on a straight-line basis over the service period, which is the vesting period. The Company estimates forfeitures that it expects will occur and records expense based upon the number of awards expected to vest. | |||
Cash and Cash Equivalents, Policy [Policy Text Block] | ' | ||
Cash and Cash Equivalents | |||
The Company classifies investments as cash equivalents if the original maturity of an investment is three months or less. | |||
Receivables, Policy [Policy Text Block] | ' | ||
Allowance for Doubtful Accounts | |||
The Company establishes an allowance for doubtful accounts to ensure trade and notes receivable are not overstated due to uncollectability. The Company’s allowance is based on a variety of factors, including age of the receivable, significant one-time events, historical experience, and other risk considerations. The Company had no material accounts receivable and no allowance at December 31, 2013 and 2012 | |||
Inventory, Policy [Policy Text Block] | ' | ||
Inventory | |||
Inventories are stated at the lower of cost or market. Cost is determined on a first-in, first-out basis. The Company continually assesses the appropriateness of inventory valuations giving consideration to slow-moving, non-saleable, out-of-date or close-dated inventory. As of December 31, 2013 and 2012 the Company had $184 and $1,058, respectively, of inventory included in other current assets. | |||
Property, Plant and Equipment, Policy [Policy Text Block] | ' | ||
Property and Equipment | |||
Property and equipment are stated on the basis of historical cost less accumulated depreciation. Depreciation is provided using the straight-line method over the two to seven year estimated useful lives of the assets. | |||
Goodwill and Intangible Assets, Goodwill, Policy [Policy Text Block] | ' | ||
Patents and Patent Expenditures | |||
AMARQ holds patent license agreements and holds patents that are owned by the Company. All patent license agreements remain in effect over the life of the underlying patents. Accordingly, the patent license fee is being amortized over the estimated life of the patent using the straight-line method. Patent fees and legal fees associated with the issuance of new owned patents are capitalized and amortized over the estimated 15 to 20 year life of the patent. The Company continually evaluates the amortization period and carrying basis of patents to determine whether subsequent events and circumstances warrant a revised estimated useful life or impairment in value. To date, no such impairment has occurred. To the extent such events or circumstances occur that could affect the recoverability of our patents, we may incur charges for impairment in the future. | |||
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] | ' | ||
Long-lived Assets | |||
Impairment losses are recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. No impairment losses have been recorded since inception. | |||
Income Tax, Policy [Policy Text Block] | ' | ||
Income Taxes | |||
The asset and liability approach is used to account for income taxes by recognizing deferred tax assets and liabilities for the expected future tax consequences of temporary differences between the carrying amounts and the tax bases of assets and liabilities. The Company records a valuation allowance to reduce the deferred tax assets to the amount that is more likely than not to be realized. | |||
Revenue Recognition, Policy [Policy Text Block] | ' | ||
Revenue Recognition | |||
Dietary supplement and interferon sales | |||
Revenues for the dietary supplement and interferon sales are recognized when an arrangement exists, the price is fixed and it has been determined that collectability is reasonably assured. This generally occurs at the point when the goods are shipped to the customer. | |||
Sublicense fee revenue | |||
Sublicense revenue is calculated based on fees relating to a license. Amarillo recognizes revenue on these sublicense fees in the month the revenue is generated by the licensee. | |||
Royalty revenue | |||
Royalty revenue is calculated based on royalty fees as a percent of net sales relating to a license. Amarillo recognizes revenue on these royalty payments in the year the revenue is generated by the licensee. HBL reported no sales of Bimron to Bio Vet for 2013 and 2012. | |||
Research and Development Expense, Policy [Policy Text Block] | ' | ||
Research and Development | |||
Research and development costs are expensed as incurred. | |||
Use of Estimates, Policy [Policy Text Block] | ' | ||
Use of Estimates | |||
The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | |||
The most significant estimates are the assumptions used in the valuation models to determine the fair value of stock-based compensation and the fair value of the derivative liability. | |||
Earnings Per Share, Policy [Policy Text Block] | ' | ||
Basic and Diluted Net Loss Per Share | |||
Net loss per share is computed by dividing the net loss by the weighted average number of common shares outstanding. In 2013 and 2012, options and warrants outstanding were antidilutive and not included in the calculation of fully diluted net loss per share. | |||
Concentration Risk, Credit Risk, Policy [Policy Text Block] | ' | ||
Concentration of Credit Risk | |||
Financial instruments that potentially subject the Company to significant concentration of credit risk consist principally of cash. | |||
The Company has cash balances in a single financial institution which, from time to time, exceed the federally insured limit of $250,000. No loss has been incurred related to this concentration of cash. | |||
Other Concentrations | |||
On March 13, 1992, we entered into a Joint Development and Manufacturing/Supply Agreement with HBL (the “Development Agreement”). As of February 1, 2012, HBL began operating under the name Hayashibara Company, Ltd. (“HBC”) as a wholly-owned subsidiary of Nagase Corporation. In correspondence received April 23, 2012, HBC informed us that they had decided to permanently halt production of interferon. Subsequently, ABI was informed that HBC was preparing a letter of notification that the Development Agreement would be terminated. On September 23, 2012, the expected notification letter was received, and the Development Agreement was officially terminated as of December 22, 2012. | |||
On October 26, 2006, we entered into a Supply Agreement Anhydrous Crystalline Maltose with HBL (the “ACM Supply Agreement”). In correspondence received September 23, 2013, HBC informed us that, in accordance with Section 3 of the ACM Supply Agreement, it would be terminated as of October 26, 2013. | |||
Among other things, the Development Agreement provided us and our sub-licensees with a source of natural human interferon alpha for use in the Company’s interferon alpha-containing products. Termination of the Development Agreement leaves the Company without a current source of interferon with which to conduct clinical trials or to supply its sub-licensees. The Company is exploring its options and is talking with alternate suppliers of interferon. | |||
Description of New Accounting Pronouncements Not yet Adopted [Text Block] | ' | ||
Recent Accounting Pronouncements | |||
Management does not anticipate that any recently issued but not yet effective accounting pronouncements will materially impact the Company’s financial condition. |
Note_2_Property_Equipment_and_1
Note 2 - Property, Equipment and Software, net (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Property, Plant and Equipment [Abstract] | ' | ||||||||
Property, Plant and Equipment [Table Text Block] | ' | ||||||||
2013 | 2012 | ||||||||
Furniture and equipment | $ | 38,221 | $ | 38,221 | |||||
Software | 8,012 | 8,012 | |||||||
46,233 | 46,233 | ||||||||
Less: accumulated depreciation | (46,233 | ) | (46,233 | ) | |||||
Property, equipment and software, net | $ | - | $ | - |
Note_3_Patents_net_Tables
Note 3 - Patents, net (Tables) | 12 Months Ended | ||||||||
Dec. 31, 2013 | |||||||||
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ||||||||
Schedule of Finite-Lived Intangible Assets [Table Text Block] | ' | ||||||||
2013 | 2012 | ||||||||
Patents | $ | 173,488 | $ | 158,429 | |||||
Less: accumulated amortization | (80,449 | ) | (64,329 | ) | |||||
Patents, net | $ | 93,039 | $ | 94,100 | |||||
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] | ' | ||||||||
2014 | $ | 16,376 | |||||||
2015 | 16,376 | ||||||||
2016 | 12,525 | ||||||||
2017 | 12,525 | ||||||||
2018 | 11,162 | ||||||||
thereafter | 24,075 | ||||||||
Total expense | $ | 93,039 |
Note_6_Common_Stock_Tables
Note 6 - Common Stock (Tables) | 12 Months Ended | |||||||||||||
Dec. 31, 2013 | ||||||||||||||
Note 6 - Common Stock (Tables) [Line Items] | ' | |||||||||||||
Schedule of Stock by Class [Table Text Block] | ' | |||||||||||||
Common Stock Issued in 2013 | Shares | Issue Price | Net Price | |||||||||||
None | - | $ | - | $ | - | |||||||||
Total Common Stock Issued in 2013 | - | $ | - | $ | - | |||||||||
Previous Year [Member] | ' | |||||||||||||
Note 6 - Common Stock (Tables) [Line Items] | ' | |||||||||||||
Schedule of Stock by Class [Table Text Block] | ' | |||||||||||||
Common Stock Issued in 2012 | Shares | Issue Price | Net Price | |||||||||||
Directors, officers, consultants plan– services | 50,000 | $0.04 | $ | 1,750 | ||||||||||
Debt conversion – cashless | 1,945,108 | $0.02 | - | 0.0208 | 74,091 | |||||||||
Total Common Stock Issued in 2012 | 1,995,108 | $0.02 | - | 0.035 | $ | 75,841 |
Note_8_Stock_Option_and_Stock_1
Note 8 - Stock Option and Stock Plans (Tables) | 12 Months Ended | |||||||||||||||
Dec. 31, 2013 | ||||||||||||||||
Disclosure of Compensation Related Costs, Share-based Payments [Abstract] | ' | |||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||||||
Stock Plans * | Issue Date Range | Total Shares Authorized | Shares Issued | Shares Remaining | ||||||||||||
2008 Stock Incentive Plan | 5/23/08 | – | 10/11/11 | 600,000 | 463,420 | 136,580 | ||||||||||
2008 Executive Officers Compensatory Stock Plan | 7/10/08 | – | 9/17/08 | 200,000 | 51,563 | 148,437 | ||||||||||
2008 Amended and Restated Directors, Officers and Consultants Stock Purchase Plan**** | 10/22/08 | – | 7/31/13 | 8,000,000 | 7,502,902 | 497,098 | ||||||||||
2009 Consultants Stock Grant Plan | 7/13/09 | – | 10/31/09 | 100,000 | 50,000 | 50,000 | ||||||||||
Non Stock Plan Issuances | 6/2/08 | – | 3/12/10 | 929,562 | 205,863 | 723,699 | ||||||||||
Stock Option Plans * | Issue Date Range | Total Options Authorized** | Options Issued | Options Remaining | ||||||||||||
2009A Officers, Directors, Employees and Consultants Nonqualified Stock Option Plan *** | 4/30/09 | – | 3/8/11 | 20,000,000 | 3,050,000 | 16,950,000 | ||||||||||
Non Stock Option Plan Issuances | 6/30/08 | – | 12/16/08 | 1,056,912 | 1,056,912 | 0 |
Note_9_Stock_Options_and_Warra1
Note 9 - Stock Options and Warrants (Tables) | 12 Months Ended | |||||||||||||||||||
Dec. 31, 2013 | ||||||||||||||||||||
Note 9 - Stock Options and Warrants (Tables) [Line Items] | ' | |||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||||||||||
Stock Plans * | Issue Date Range | Total Shares Authorized | Shares Issued | Shares Remaining | ||||||||||||||||
2008 Stock Incentive Plan | 5/23/08 | – | 10/11/11 | 600,000 | 463,420 | 136,580 | ||||||||||||||
2008 Executive Officers Compensatory Stock Plan | 7/10/08 | – | 9/17/08 | 200,000 | 51,563 | 148,437 | ||||||||||||||
2008 Amended and Restated Directors, Officers and Consultants Stock Purchase Plan**** | 10/22/08 | – | 7/31/13 | 8,000,000 | 7,502,902 | 497,098 | ||||||||||||||
2009 Consultants Stock Grant Plan | 7/13/09 | – | 10/31/09 | 100,000 | 50,000 | 50,000 | ||||||||||||||
Non Stock Plan Issuances | 6/2/08 | – | 3/12/10 | 929,562 | 205,863 | 723,699 | ||||||||||||||
Stock Option Plans * | Issue Date Range | Total Options Authorized** | Options Issued | Options Remaining | ||||||||||||||||
2009A Officers, Directors, Employees and Consultants Nonqualified Stock Option Plan *** | 4/30/09 | – | 3/8/11 | 20,000,000 | 3,050,000 | 16,950,000 | ||||||||||||||
Non Stock Option Plan Issuances | 6/30/08 | – | 12/16/08 | 1,056,912 | 1,056,912 | 0 | ||||||||||||||
Employee Stock Option [Member] | ' | |||||||||||||||||||
Note 9 - Stock Options and Warrants (Tables) [Line Items] | ' | |||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||||||||||
Shares | Weighted | Weighted Average Remaining Contractual Life (in Years) | Grant Date Fair Value | |||||||||||||||||
Average | ||||||||||||||||||||
Exercise Price | ||||||||||||||||||||
Outstanding at December 31, 2011 | 3,641,792 | $ | 0.07 | 3.84 | $ | 238,850 | ||||||||||||||
Options granted | - | - | - | - | ||||||||||||||||
Options exercised | - | - | - | - | ||||||||||||||||
Options cancelled/expired | (1,789,000 | ) | (0.08 | ) | - | (134,167 | ) | |||||||||||||
Outstanding at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Vested at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Exercisable at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Outstanding at December 31, 2012 | 1,852,792 | $ | 0.06 | 3.24 | $ | 104,683 | ||||||||||||||
Options granted | - | - | - | - | ||||||||||||||||
Options exercised | - | - | - | - | ||||||||||||||||
Options cancelled/expired | (100,000 | ) | 0.08 | - | (7,280 | ) | ||||||||||||||
Outstanding at December 31, 2013 | 1,752,792 | $ | 0.06 | 2.41 | $ | 97,403 | ||||||||||||||
Vested at December 31, 2013 | 1,752,792 | $ | 0.06 | 2.41 | $ | 97,403 | ||||||||||||||
Outstanding at December 31, 2013 | 1,752,792 | $ | 0.06 | 2.41 | $ | 97,403 | ||||||||||||||
Stock Warrants [Member] | ' | |||||||||||||||||||
Note 9 - Stock Options and Warrants (Tables) [Line Items] | ' | |||||||||||||||||||
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block] | ' | |||||||||||||||||||
2013 | 2012 | |||||||||||||||||||
Warrants | Price Range | Warrants | Price Range | |||||||||||||||||
Outstanding Beg. of Year | 6,642,317 | $ | 0.0202 | - | 0.1 | 8,730,190 | $ | 0.03 | - | 0.1 | ||||||||||
Granted | - | - | 724,487 | 0.0202 | ||||||||||||||||
Cancelled/Expired | (4,354,817 | ) | $ | -0.0202 | - | -0.1 | (2,812,360 | ) | -0.1 | |||||||||||
Exercised | - | - | - | - | ||||||||||||||||
Outstanding End of Year | 2,287,500 | $ | 0.03 | - | 0.04 | 6,642,317 | $ | 0.0202 | - | 0.1 | ||||||||||
Exercisable End of Year | 2,287,500 | $ | 0.03 | - | 0.04 | 6,642,317 | $ | 0.0202 | - | 0.1 |
Note_1_Organization_and_Summar1
Note 1 - Organization and Summary of Significant Accounting Policies (Details) (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Apr. 15, 2014 | |
Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items] | ' | ' | ' |
Assets | $161,531 | $115,035 | $101,089 |
Liabilities | 4,944,318 | 4,242,330 | 4,787,127 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | 0 | 0 | ' |
Provision for Doubtful Accounts | 182 | ' | ' |
Inventory, Gross | $184 | $1,058 | ' |
Minimum [Member] | ' | ' | ' |
Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items] | ' | ' | ' |
Property, Plant and Equipment, Estimated Useful Lives | 'two | ' | ' |
Finite-Lived Intangible Asset, Useful Life | '15 years | ' | ' |
Maximum [Member] | ' | ' | ' |
Note 1 - Organization and Summary of Significant Accounting Policies (Details) [Line Items] | ' | ' | ' |
Property, Plant and Equipment, Estimated Useful Lives | 'seven | ' | ' |
Finite-Lived Intangible Asset, Useful Life | '20 years | ' | ' |
Note_2_Property_Equipment_and_2
Note 2 - Property, Equipment and Software, net (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Property, Plant and Equipment [Abstract] | ' | ' |
Depreciation | $0 | $42 |
Note_2_Property_Equipment_and_3
Note 2 - Property, Equipment and Software, net (Details) - Equipment (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Equipment [Abstract] | ' | ' |
Furniture and equipment | $38,221 | $38,221 |
Software | 8,012 | 8,012 |
46,233 | 46,233 | |
Less: accumulated depreciation | ($46,233) | ($46,233) |
Note_3_Patents_net_Details
Note 3 - Patents, net (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ' | ' |
Amortization of Intangible Assets | $16,120 | $15,530 |
Note_3_Patents_net_Details_Pat
Note 3 - Patents, net (Details) - Patents (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Patents [Abstract] | ' | ' |
Patents | $173,488 | $158,429 |
Less: accumulated amortization | -80,449 | -64,329 |
Patents, net | $93,039 | $94,100 |
Note_3_Patents_net_Details_Est
Note 3 - Patents, net (Details) - Estimated Future Amortization Expense (USD $) | Dec. 31, 2013 | Dec. 31, 2012 |
Estimated Future Amortization Expense [Abstract] | ' | ' |
2014 | $16,376 | ' |
2015 | 16,376 | ' |
2016 | 12,525 | ' |
2017 | 12,525 | ' |
2018 | 11,162 | ' |
thereafter | 24,075 | ' |
Total expense | $93,039 | $94,100 |
Note_4_Notes_Payable_Details
Note 4 - Notes Payable (Details) (USD $) | 1 Months Ended | 2 Months Ended | 10 Months Ended | 11 Months Ended | 12 Months Ended | 3 Months Ended | 0 Months Ended | 5 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 2 Months Ended | 10 Months Ended | 11 Months Ended | 12 Months Ended | ||||||||||||||||||||
Jul. 29, 2010 | Dec. 31, 2013 | Oct. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2010 | Oct. 31, 2012 | Feb. 08, 2012 | Aug. 28, 2008 | Apr. 15, 2014 | Jan. 15, 2014 | Feb. 08, 2012 | Feb. 08, 2012 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Jul. 25, 2013 | Jul. 19, 2013 | Jul. 19, 2013 | Jul. 19, 2013 | Oct. 31, 2013 | Jun. 03, 2008 | Jul. 22, 1999 | Aug. 28, 2008 | Feb. 08, 2012 | Jan. 23, 2012 | Dec. 31, 2013 | Oct. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Jan. 10, 2011 | Dec. 31, 2013 | |
Subsequent Event [Member] | Subsequent Event [Member] | Series A Preferred Stock [Member] | Series A Preferred Stock [Member] | Paul Tibbits Promissory Note [Member] | Stephen Chen [Member] | Stephen Chen [Member] | Stephen Chen [Member] | Stephen Chen [Member] | Stephen Chen [Member] | Stephen Chen [Member] | Accounts Payable and Accrued Liabilities [Member] | Loan 1 [Member] | Loan 1 [Member] | Loan 2 [Member] | Paul Tibbits Promissory Note [Member] | Paul Tibbits Promissory Note [Member] | Paul Tibbits Promissory Note [Member] | Paul Tibbits Promissory Note [Member] | Paul Tibbits Promissory Note [Member] | Paul Tibbits Promissory Note [Member] | Paul Tibbits Promissory Note [Member] | Paul Tibbits Promissory Note [Member] | Wells Fargo [Member] | ||||||||||||
Paul Tibbits Promissory Note [Member] | On Unpaid Principal Amount [Member] | On Material Unpaid Amounts [Member] | Wells Fargo [Member] | ||||||||||||||||||||||||||||||||
Note 4 - Notes Payable (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Notes Payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | $85,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $1,000,000 | $1,000,000 | $1,000,000 | ' | ' | ' | ' | ' | ' | ' | $0.00 | ' |
Debt Instrument, Interest Rate, Stated Percentage | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.23% | 10.00% | ' | ' | 4.50% | ' | ' | ' | 10.00% | ' | ' | 10.00% | ' | ' | ' |
Line of Credit Facility, Maximum Borrowing Capacity | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | 285,000 | ' | ' | ' | ' | ' | 300,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 20,000 |
Line of Credit Facility, Amount Outstanding | ' | ' | 3,006,752.88 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 18,376 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in Shares) | ' | ' | ' | ' | ' | ' | ' | 12,000,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payments for Repurchase of Warrants | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Interest Payable | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 200,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 35,055.56 | ' | ' | 35,055.56 | ' | ' | ' |
Debt Conversion, Converted Instrument, Shares Issued (in Shares) | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 850 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 0.1 | ' | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Dividend Rate, Percentage | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 10.00% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Payments of Ordinary Dividends, Preferred Stock and Preference Stock | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 48,878 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Conversion, Converted Instrument, Amount | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 489 | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from Related Party Debt | ' | ' | ' | ' | 765,835 | 557,958 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 428,835 | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,339 | ' | ' | ' | ' | ' | ' | ' |
Preferred Stock, Amount of Preferred Dividends in Arrears | ' | ' | ' | ' | 63,241 | ' | 16,956 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 5,398 | 26,992 | 30,851 | ' | ' | ' | ' |
Interest Expense, Other | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 1,458 | 4,628 | ' | ' |
Interest Expense, Debt | ' | 547,958 | 16,889 | 18,167 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Notes Payable, Related Parties | ' | ' | ' | ' | ' | ' | ' | ' | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 976,793 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Related Party Transaction, Amounts of Transaction | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | 280,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Proceeds from Lines of Credit | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | $164,972 | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Debt Instrument, Basis Spread on Variable Rate | ' | ' | ' | ' | 6.75% | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_5_License_Sublicense_Manu1
Note 5 - License, Sublicense, Manufacturing, Research and Supply Agreements (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Oct. 31, 2012 | |
Note 5 - License, Sublicense, Manufacturing, Research and Supply Agreements (Details) [Line Items] | ' | ' |
Royalty Expense | $7,500 | ' |
Due to Related Parties | 78,360 | 236,732 |
Texas A&M University [Member] | ' | ' |
Note 5 - License, Sublicense, Manufacturing, Research and Supply Agreements (Details) [Line Items] | ' | ' |
Royalty Expense | $22,500 | ' |
Note_6_Common_Stock_Details
Note 6 - Common Stock (Details) | Dec. 31, 2013 | Dec. 31, 2012 |
Stockholders' Equity Note [Abstract] | ' | ' |
Common Stock, Shares Authorized | 100,000,000 | 100,000,000 |
Common Stock Outstanding Or Reserved For Future Issuance | 80,593,300 | ' |
Note_6_Common_Stock_Details_Su
Note 6 - Common Stock (Details) - Summary of Common Stock Issuances (USD $) | 0 Months Ended | 12 Months Ended | |
Feb. 06, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Summary of Common Stock Issuances [Abstract] | ' | ' | ' |
Shares | 693,069 | 0 | 1,995,108 |
Issue Price | ' | $0 | ' |
Net Price | ' | $0 | $75,841 |
Note_6_Common_Stock_Details_Su1
Note 6 - Common Stock (Details) - Summary of Common Stock Issuances - Prior Year (USD $) | 0 Months Ended | 12 Months Ended | |
Feb. 06, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Class of Stock [Line Items] | ' | ' | ' |
Shares (in Shares) | 693,069 | 0 | 1,995,108 |
Issue Price | ' | $0 | ' |
Net Price (in Dollars) | ' | $0 | $75,841 |
Directors, Officers, Consultants - Services [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Shares (in Shares) | ' | ' | 50,000 |
Issue Price | ' | ' | $0.04 |
Net Price (in Dollars) | ' | ' | 1,750 |
Debt Conversion - Cashless [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Shares (in Shares) | ' | ' | 1,945,108 |
Net Price (in Dollars) | ' | ' | $74,091 |
Debt Conversion - Cashless [Member] | Minimum [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Issue Price | ' | ' | $0.02 |
Debt Conversion - Cashless [Member] | Maximum [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Issue Price | ' | ' | $0.02 |
Minimum [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Issue Price | ' | ' | $0.02 |
Maximum [Member] | ' | ' | ' |
Class of Stock [Line Items] | ' | ' | ' |
Issue Price | ' | ' | $0.04 |
Note_7_Preferred_Stock_Details
Note 7 - Preferred Stock (Details) (USD $) | 0 Months Ended | 1 Months Ended | 12 Months Ended | ||
Feb. 06, 2012 | Jul. 29, 2010 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Note 7 - Preferred Stock (Details) [Line Items] | ' | ' | ' | ' | ' |
Preferred Stock, Shares Authorized | ' | 10,000 | 10,000,000 | 10,000,000 | ' |
Convertible Preferred Stock, Shares Issued upon Conversion | ' | 1,000 | ' | 1,562,000 | 200,000 |
Preferred Stock, Redemption Price Per Share (in Dollars per share) | ' | $100 | ' | ' | ' |
Preferred Stock, Liquidation Preference Per Share (in Dollars per share) | ' | $0.10 | ' | ' | ' |
Preferred Stock, Dividend Rate, Percentage | ' | 10.00% | ' | ' | ' |
Preferred Stock, Dividends, Per Share, Cash Paid (in Dollars per share) | ' | $0.10 | ' | ' | ' |
Stock Issued During Period, Shares, New Issues | 693,069 | ' | 0 | 1,995,108 | ' |
Dividends, Preferred Stock (in Dollars) | ' | ' | $32,390 | $30,851 | $16,956 |
Preferred Stock, Shares Outstanding | ' | ' | 3,262 | 3,262 | 1,700 |
Preferred Stock, Amount of Preferred Dividends in Arrears (in Dollars) | ' | ' | 63,241 | ' | 16,956 |
Stock Issued During Period, Value, New Issues (in Dollars) | ' | ' | 0 | 75,841 | ' |
Convertible Preferred Stock [Member] | ' | ' | ' | ' | ' |
Note 7 - Preferred Stock (Details) [Line Items] | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, New Issues | ' | ' | ' | 1,562 | 200 |
Issued For Cash [Member] | ' | ' | ' | ' | ' |
Note 7 - Preferred Stock (Details) [Line Items] | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, New Issues | ' | ' | ' | 223 | ' |
Stock Issued During Period, Value, New Issues (in Dollars) | ' | ' | ' | 20,000 | ' |
Issued For Debt [Member] | ' | ' | ' | ' | ' |
Note 7 - Preferred Stock (Details) [Line Items] | ' | ' | ' | ' | ' |
Stock Issued During Period, Shares, New Issues | ' | ' | ' | 1,339 | ' |
Loan Principal [Member] | ' | ' | ' | ' | ' |
Note 7 - Preferred Stock (Details) [Line Items] | ' | ' | ' | ' | ' |
Stock Issued During Period, Value, New Issues (in Dollars) | ' | ' | ' | 85,000 | ' |
Interest And Dividends [Member] | ' | ' | ' | ' | ' |
Note 7 - Preferred Stock (Details) [Line Items] | ' | ' | ' | ' | ' |
Stock Issued During Period, Value, New Issues (in Dollars) | ' | ' | ' | $48,878 | ' |
Note_8_Stock_Option_and_Stock_2
Note 8 - Stock Option and Stock Plans (Details) (ABI [Member], Pan Consulting, Ltd. [Member], USD $) | 0 Months Ended |
Jul. 12, 2013 | |
ABI [Member] | Pan Consulting, Ltd. [Member] | ' |
Note 8 - Stock Option and Stock Plans (Details) [Line Items] | ' |
Payments for Repurchase of Equity | $5,500 |
Shares, Issued | 263,889 |
Note_8_Stock_Option_and_Stock_3
Note 8 - Stock Option and Stock Plans (Details) - Stock Option Plan Summary | 12 Months Ended | 41 Months Ended | 2 Months Ended | 57 Months Ended | 3 Months Ended | 21 Months Ended | 22 Months Ended | 6 Months Ended | ||||||||
Dec. 31, 2013 | Dec. 31, 2012 | Oct. 11, 2011 | Sep. 17, 2008 | Jul. 31, 2013 | Oct. 31, 2009 | Mar. 12, 2010 | Mar. 08, 2011 | Dec. 16, 2008 | ||||||||
2008 Stock Incentive Plan [Member] | 2008 Executive Officers Compensatory Stock Plan [Member] | 2008 Amended And Restated Directors, Officers And Consultans Stock Purchase Plan [Member] | 2009 Consultants Stock Grant Plan [Member] | Non Stock Plan Issuances [Member] | 2009A Officers, Directors, Employees And Consultants Nonqualified Stock Option Plan [Member] | Non Stock Option Plan Issuances [Member] | ||||||||||
Note 8 - Stock Option and Stock Plans (Details) - Stock Option Plan Summary [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | |||||||
Total Shares Authorized | ' | ' | 600,000 | [1] | 200,000 | [1] | 8,000,000 | [1],[2] | 100,000 | [1] | 929,562 | [1] | 20,000,000 | [1],[3],[4] | 1,056,912 | [1],[3] |
Shares Issued | 0 | 0 | 463,420 | [1] | 51,563 | [1] | 7,502,902 | [1],[2] | 50,000 | [1] | 205,863 | [1] | 3,050,000 | [1],[4] | 1,056,912 | [1] |
Shares Remaining | ' | ' | 136,580 | [1] | 148,437 | [1] | 497,098 | [1],[2] | 50,000 | [1] | 723,699 | [1] | 16,950,000 | [1],[4] | 0 | [1] |
[1] | The Board of Directors has approved all stock, stock option and stock warrant issuances. | |||||||||||||||
[2] | On July 12, 2013, ABI and PAN Consulting, Ltd. entered into and executed a Settlement Agreement and Release whereby ABI paid $5,500 in full and final settlement of any and all claims held or asserted by PAN Consulting, Ltd. and PAN Consulting, Ltd. agreed to endorse and deliver to ABI any and all stock certificates evidencing an aggregate of 263,889 shares of ABI common stock. The terms of the agreement also included termination of the contract executed in 2006 by the parties. The shares were returned to the Plan. | |||||||||||||||
[3] | One option reserves one share of common stock. | |||||||||||||||
[4] | This plan replaces and supersedes in their entirety the Company's Outside Director and Advisor Stock Option Plan, as amended and restated as of May 11, 1999; the Company's 1996 Employee's Stock Option Plan, as amended and restated as of May 11, 1999; and the Company's First Amended 2006 Employee's Stock Option and Stock Bonus Plan; provided however, that options already issued and outstanding under said superseded plans shall continue to be outstanding and exercisable in accordance with their terms, as such may have been extended or re-priced from time to time, and the terms of any applicable option agreements entered into between the Company and the Optionee. |
Note_9_Stock_Options_and_Warra2
Note 9 - Stock Options and Warrants (Details) (USD $) | 0 Months Ended | 12 Months Ended | |
Feb. 06, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | ' | 0 | 0 |
Warrants Issued (in Shares) | 724,487 | ' | ' |
Debt Conversion, Converted Instrument, Warrants or Options Issued (in Shares) | 693,069 | ' | 110,300 |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item) | 0.0202 | ' | ' |
Base Share Price (in Dollars per share) | $0.02 | ' | ' |
Warrants and Rights Outstanding | ' | ' | $2,217,817 |
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | ' | '361 days | ' |
Stock Issued During Period, Shares, New Issues (in Shares) | 693,069 | 0 | 1,995,108 |
Share Price (in Dollars per share) | $0.02 | ' | ' |
Fair Vaule Assumption Probability of Anti-Dilution Ratchet | ' | ' | 75.00% |
Fair Value Assumptions Probable Reset Share Price (in Dollars per share) | ' | ' | $0.02 |
Fair Value Assumptions, Expected Dividend Rate | ' | ' | 0.00% |
Fair Value Assumptions, Expected Volatility Rate | ' | ' | 234.76% |
Fair Value Assumptions, Risk Free Interest Rate | ' | ' | 0.14% |
Fair Value Assumptions, Expected Term | ' | ' | '7 days |
Warrants Not Settleable in Cash, Fair Value Disclosure | ' | ' | 4,217 |
Warrants Returned To Equity Value | ' | ' | 17,035 |
Derivative, Gain on Derivative | ' | 4,217 | 44,096 |
Series 1 [Member] | Additional Warrants [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Warrants and Rights Outstanding | 724,487 | ' | ' |
Series 1 [Member] | Existing Warrants [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Warrants and Rights Outstanding | 1,493,330 | ' | ' |
Series 1 [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item) | 0.0202 | ' | ' |
Warrants and Rights Outstanding | 2,217,817 | ' | ' |
Series 2 [Member] | Additional Warrants [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Warrants and Rights Outstanding | 724,487 | ' | ' |
Series 2 [Member] | Existing Warrants [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Warrants and Rights Outstanding | 1,493,330 | ' | ' |
Series 2 [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Class of Warrant or Right, Exercise Price of Warrants or Rights (in Dollars per Item) | 0.0202 | ' | ' |
Warrants and Rights Outstanding | $2,217,817 | ' | ' |
Issued To Consultants [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares) | ' | 0 | 0 |
Directors, Officers and Consultants [Member] | ' | ' | ' |
Note 9 - Stock Options and Warrants (Details) [Line Items] | ' | ' | ' |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in Shares) | ' | 0 | 0 |
Note_9_Stock_Options_and_Warra3
Note 9 - Stock Options and Warrants (Details) - Stock Option Activity (USD $) | 12 Months Ended | ||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Stock Option Activity [Abstract] | ' | ' | ' |
Shares Outstanding | 1,852,792 | 1,852,792 | 3,641,792 |
Weighted Average Exercise Price of Shares Outstanding | $0.06 | $0.06 | $0.07 |
Weighted Average Remaining Contractual Life of Shares Outstanding | '2 years 149 days | '3 years 87 days | '3 years 306 days |
Grant Date Fair Value of Shares Outstanding | $104,683 | $104,683 | $238,850 |
Shares Cancelled/Expired | -100,000 | -1,789,000 | ' |
Weighted Average Exercise Price of Shares Cancelled/Expired | $0.08 | ($0.08) | ' |
Grant Date Fair Value of Shares Cancelled/Expired | -7,280 | -134,167 | ' |
Shares Outstanding | 1,752,792 | 1,852,792 | 1,852,792 |
Weighted Average Exercise Price of Shares Outstanding | $0.06 | $0.06 | $0.06 |
Weighted Average Remaining Contractual Life of Shares Outstanding | '2 years 149 days | '3 years 87 days | '3 years 306 days |
Grant Date Fair Value of Shares Outstanding | 97,403 | 104,683 | 104,683 |
Shares Vested | 1,752,792 | 1,852,792 | ' |
Weighted Average Exercise Price of Shares Vested | $0.06 | $0.06 | ' |
Weighted Average Remaining Contractual Life of Shares Vested | '2 years 149 days | '3 years 87 days | ' |
Grant Date Fair Value of Shares Vested | 97,403 | 104,683 | ' |
Exercisable at December 31, 2012 | ' | 1,852,792 | ' |
Exercisable at December 31, 2012 | ' | $0.06 | ' |
Exercisable at December 31, 2012 | ' | '3 years 87 days | ' |
Exercisable at December 31, 2012 | ' | $104,683 | ' |
Note_9_Stock_Options_and_Warra4
Note 9 - Stock Options and Warrants (Details) - Stock Warrant Activity (USD $) | 12 Months Ended | 12 Months Ended | 12 Months Ended | ||||||
Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2010 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2011 | |
Minimum [Member] | Minimum [Member] | Minimum [Member] | Maximum [Member] | Maximum [Member] | Maximum [Member] | ||||
Note 9 - Stock Options and Warrants (Details) - Stock Warrant Activity [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Warrants (in Shares) | 6,642,317 | 8,730,190 | ' | ' | ' | ' | ' | ' | ' |
Weighted Average Exercise Price of Shares Outstanding | $0.06 | $0.06 | $0.07 | $0.02 | ' | $0.03 | $0.10 | ' | $0.10 |
Exercisable End of Year (in Shares) | 2,287,500 | 6,642,317 | ' | ' | ' | ' | ' | ' | ' |
Exercisable End of Year | ' | ' | ' | $0.03 | $0.02 | ' | $0.04 | $0.10 | ' |
Granted (in Shares) | ' | 724,487 | ' | ' | ' | ' | ' | ' | ' |
Granted | ' | $0.02 | ' | ' | ' | ' | ' | ' | ' |
Cancelled/Expired (in Shares) | -4,354,817 | -2,812,360 | ' | ' | ' | ' | ' | ' | ' |
Cancelled/Expired | ' | ($0.10) | ' | ($0.02) | ' | ' | ($0.10) | ' | ' |
Warrants (in Shares) | 2,287,500 | 6,642,317 | ' | ' | ' | ' | ' | ' | ' |
Weighted Average Exercise Price of Shares Outstanding | $0.06 | $0.06 | $0.07 | $0.03 | ' | $0.03 | $0.04 | ' | $0.10 |
Note_10_Income_Taxes_Details
Note 10 - Income Taxes (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
Income Tax Disclosure [Abstract] | ' | ' |
Deferred Tax Assets, Gross | $7,742,000 | $7,540,000 |
Deferred Tax Assets, Valuation Allowance | 7,742,000 | 7,540,000 |
Valuation Allowance, Deferred Tax Asset, Change in Amount | 202,000 | -430,000 |
Operating Loss Carryforwards | $22,770,000 | $22,176,000 |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 0.00% | ' |
Note_11_Commitments_and_Contin1
Note 11 - Commitments and Contingencies (Details) (USD $) | 12 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | |
sqft | ||
Note 11 - Commitments and Contingencies (Details) [Line Items] | ' | ' |
Notes Payable, Related Parties, Current | $3,527,043 | $2,847,958 |
Waiver Of Claim To Unpaid Salary | ' | 267,811 |
Area of Real Estate Property (in Square Feet) | 1,800 | ' |
Operating Leases, Rent Expense | 1,045 | ' |
Royalty Expense | 7,500 | ' |
Martin Cummins [Member] | ' | ' |
Note 11 - Commitments and Contingencies (Details) [Line Items] | ' | ' |
Unpaid Salaries | ' | 143,300 |
Notes Payable, Related Parties, Current | 13,250 | 100,000 |
Other Officer [Member] | ' | ' |
Note 11 - Commitments and Contingencies (Details) [Line Items] | ' | ' |
Unpaid Salaries | ' | 13,222 |
Delinquent Payroll [Member] | ' | ' |
Note 11 - Commitments and Contingencies (Details) [Line Items] | ' | ' |
Unpaid Salaries | ' | 113,222 |
Other Accrued Liabilities, Current | ' | 13,222 |
Notes Payable, Related Parties, Current | ' | $100,000 |
Note_12_Related_Party_Transact1
Note 12 - Related Party Transactions (Details) (USD $) | 1 Months Ended | 12 Months Ended | 13 Months Ended | 12 Months Ended | 6 Months Ended | 13 Months Ended | ||||
Oct. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2012 | Dec. 31, 2013 | Dec. 31, 2013 | Dec. 31, 2012 | Nov. 30, 2012 | Nov. 30, 2012 | Nov. 30, 2012 | Dec. 31, 2013 | |
HBL [Member] | HBL [Member] | Joseph Cummins [Member] | Joseph Cummins [Member] | Joseph Cummins [Member] | Joseph Cummins [Member] | |||||
Monthly [Member] | Yearly [Member] | |||||||||
Note 12 - Related Party Transactions (Details) [Line Items] | ' | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Due to Related Parties | $236,732 | $78,360 | ' | $78,360 | $78,360 | ' | ' | ' | ' | ' |
Related Party Transaction, Rate | ' | ' | ' | ' | 8.00% | ' | ' | ' | ' | ' |
Revenue from Related Parties | ' | ' | ' | ' | 0 | 0 | ' | ' | ' | ' |
Related Party Transaction, Amounts of Transaction | ' | ' | ' | ' | ' | ' | 5,000 | 60,000 | 175,000 | 5,000 |
Waiver Of Claim To Unpaid Salary | ' | ' | 267,811 | ' | ' | ' | ' | ' | 278,259 | ' |
Forgivness Of Employee Receivable | ' | ' | ' | ' | ' | ' | ' | ' | 10,448 | ' |
136,732 | ' | 411,111 | ' | ' | ' | ' | ' | ' | ' | |
Notes Payable, Related Parties | 100,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Repayments of Related Party Debt | ' | $86,750 | $10,000 | $40,000 | ' | ' | ' | ' | ' | ' |
Number Of Stock Options Returned (in Shares) | 879,000 | ' | ' | ' | ' | ' | ' | ' | ' | ' |
Note_13_Subsequent_Events_Deta
Note 13 - Subsequent Events (Details) (USD $) | 12 Months Ended | 3 Months Ended | |
Dec. 31, 2013 | Dec. 31, 2012 | Apr. 15, 2014 | |
Subsequent Event [Member] | |||
The Yang Group [Member] | |||
Note 13 - Subsequent Events (Details) [Line Items] | ' | ' | ' |
Proceeds from Related Party Debt | $765,835 | $557,958 | $107,972 |